Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Inks Early-Stage Research Deal with Pfizer

Premium

MDRNA announced this week that it has begun a research study with Pfizer focused on RNAi drug discovery.

Under the deal, MDRNA will formulate Pfizer's oligonucleotides in its proprietary di-alkylated amino acids, or DiLA2, delivery vehicles for in vivo evaluation by the drugs giant. MDRNA will also design and synthesize UsiRNAs, duplex RNAs containing at least one non-nucleotide monomer, against Pfizer-specified targets.

Additional terms were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.